Dr. Stamey is Professor and the Founding Chairman of the Department of Urology at Stanford University School of Medicine, one of the top urology programs in the nation. Dr. Stamey is considered to be the single most revered urologist and prostate cancer expert in the world. In 1989, he was the first urologist elected to the Institute of Medicine of the National Academy of Sciences. In 1995, he received the Ramon Guiteras Award from the American Urological Association, the highest award given to one person annually, and in 2004, he received the prestigious Keyes Medal from the distinguished Society of Genitourinary Surgeons. In addition, Dr. Stamey was inducted into the Johns Hopkins Society of Scholars, was a Visiting Professor at the Royal Society of Medicine in London, England, and is an Honorary Fellow of the Royal College of Surgeons in Edinburgh.
Dr. Stamey received his undergraduate degree from Vanderbilt University and earned his Doctor of Medicine degree from Johns Hopkins University School of Medicine where he became an Associate Professor of Urology before becoming Professor of Surgery and Chairman of the Division of Urology at Stanford University School of Medicine in 1964. He continued his distinguished career at Stanford and was Professor and Chairman of the Department of Urology until 1994. He currently holds the Thomas A. Stamey Endowed Research Chair in Urology at Stanford University School of Medicine.
During his outstanding academic career, Dr. Stamey has published over 250 scientific papers in many prestigious medical journals including The New England Journal of Medicine. In addition, he has developed many individual urological procedures and instruments, a number of which bear his name. His primary interest is in the area of prostate cancer.
Dr. Stamey's laboratory at Stanford University Medical Center is dedicated exclusively to prostate cancer. His full-time research staff works at both the protein and gene level in prostate cancer. His research currently emphasizes the urgent need for a new serum marker for prostate cancer to replace serum PSA; his group has recently shown that serum PSA is no longer related to prostate cancer in the United States, reflecting only the benign enlargement of the prostate (this data has been accepted for publication in the October issue of the Journal of Urology).
|